secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2025-12-17T23:59:59+00:00
Accession:  0001683168-25-009208
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharmaceuticals appoints Rami Levin as CEO effective January 1, 2026; John Climaco resigns
--------------------------------------------------------------------------------

- Rami Levin becomes CEO and President effective Jan 1, 2026; base salary $580,000, target bonus 50% of base, initial RSU grant of 19,000 shares.
- John Climaco resigned as CEO and board member Dec 16, 2025; resignation not due to disagreement; severance includes 12 months salary and $319,000 bonus.
- Levin will also join the board; previously CEO of Saniona (2019-2022) and ImStem Biotechnology (2022-2024).
- If Levin is terminated without cause or for good reason, severance includes 12 months base salary, target bonus, accelerated equity vesting, and COBRA subsidy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316825009208/0001683168-25-009208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316825009208/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-009208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer